Results 31 to 40 of about 4,936 (166)
Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.ABSTRACT Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such as statins.
Hang Yang +9 more
wiley +1 more source
FASEB BioAdvances, Volume 7, Issue 6, June 2025.Prolonged fasting and fibrate treatment induce peroxisomal β‐oxidation and lead to excessive generation of hydrogen peroxide, which stimulates ethanol metabolism and significantly increases the formation of acetaldehyde; further oxidation of acetaldehyde into acetate remarkably elevates the mitochondrial ratio of NADH/NAD+ and causes feedback ...
Yida Zhang +6 more
wiley +1 more source
British Journal of Pharmacology, Volume 182, Issue 12, Page 2682-2693, June 2025.Background and Purpose The human sweet taste receptor, TAS1R2–TAS1R3, conveys sweet taste in the mouth and may help regulate glucose metabolism throughout the body. Ibuprofen and naproxen are structurally similar to known inhibitors of TAS1R2–TAS1R3 and have been associated with metabolic benefits.
Emily C. Hanselman +6 more
wiley +1 more source
A Hypothesis: Metabolic Contributions to 16p11.2 Deletion Syndrome
BioEssays, Volume 47, Issue 3, March 2025.16p11.2 Deletion syndrome is associated with brain, body, and behavioral symptoms. A majority of 16p11.2 genes relate to metabolism, involving amino acids/proteins, DNA, RNA, catabolism, lipids, and carbohydrates. Additional contributions include changes in cell structure, signaling, development, immune system, nervous system, and localization.
Brandon Kar Meng Choo +2 more
wiley +1 more source
Regulation of liver fatty acid binding protein expression by clofibrate in hepatoma cells
, 2010 Peroxisome proliferator-activated receptor (PPAR) agonists such as clofibrate are known to affect liver fatty acid binding protein (L-FABP) levels, which in turn influence hepatocellular oxidant status.
Guqi Wang +4 more
core +1 more source
Journal of Cellular and Molecular Medicine, Volume 29, Issue 5, March 2025.ABSTRACT Alzheimer's disease (AD) is a neurodegenerative disease caused by the progressive deposition of extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles (NFTs). Of note, metabolic disorders such as insulin resistance (IR) and type 2 diabetes (T2D) are associated with the development of brain IR and associated neurodegeneration.
Mansour A. Alsaleem +9 more
wiley +1 more source
, 1989 The hypolipidemic drug clofibrate is known to affect the hepatic transport of various organic anions including bilirubin, fatty acids and sulfobromophthalein.
Nathan M. Bass +10 more
core +1 more source
Journal of General and Family Medicine, Volume 26, Issue 1, Page 54-64, January 2025.This manuscript is a study demonstrating the association between the progression of severe periodontal diseases and chronic diseases commonly addressed in primary care. We used claims data and defined the outcome as the “progression of severe periodontitis” and followed patients for 4 years.
Sayaka Nin +8 more
wiley +1 more source
Influence of clofibrate on serum triptophan in man
, 1974 The effect of clofibrate on free and bound tryptophan levels was tested in 8 volunteers, 5 of whom were hospitalised. Comparing the effects of the drug, administered for 5 days, with those of a placebo, given for 5 further days, after an interval of 2 ...
G. Pozza +3 more
core +1 more source
Involvement of Inflammatory Cytokines in Antiarrhythmic Effects of Clofibrate in Ouabain-Induced Arrhythmia in Isolated Rat Atria [PDF]
, 2016 Considering the cardioprotective and anti-inflammatory properties of clofibrate, the aim of the present experiment was to investigate the involvement of local and systemic inflammatory cytokines in possible antiarrhythmic effects of clofibrate in ouabain-
Amiri, S. +11 more
core +1 more source